Answers are grounded in this paper and cite their sources.
Antibody-drug conjugates (ADCs) are considered as next-generation antibody medicine. At present, heterogeneous ADCs are available; however, their safety and efficacy are suboptimal. Homogeneous ADCs offer increased efficacy, reproducibility, and predictability of their pharmacokinetic and pharmacodynamic effects. The presence of N-glycan in the fragment crystallizable (Fc) region affects antibody function and understanding the mechanisms underlying this effect is critical for improvement of antibody therapy. In this mini-review, we described recent progress towards creation of homogeneous glycan-conjugated ADCs. The glycan-conjugated ADCs possess homogeneity in their drug-antibody ratio and structure. In addition, homogeneous glycan-conjugated ADCs exhibit potent cytotoxicity in vitro.
No takes yet. Share an insight, caveat, or question.
Shino Manabe (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: